Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14435078 | 0.78 | LMNA (0.43) | KDM4EALDH1A1 | |
| SCHEMBL19078876 | 0.78 | — | — | |
| SCHEMBL7235694 | 0.77 | KDM4E (0.42) | KDM4EALDH1A1 | |
| SCHEMBL2110629 | 0.77 | KDM4E (0.42) | KDM4EALDH1A1 | |
| SCHEMBL2454342 | 0.76 | HTT (0.38) | — | |
| SCHEMBL16414383 | 0.74 | IDO1 (0.30) | — | |
| SCHEMBL2323075 | 0.74 | — | — | |
| SCHEMBL22890017 | 0.73 | MAPK1 (0.41) | KDM4EALDH1A1 | |
| SCHEMBL29771532 | 0.73 | MAPK1 (0.41) | KDM4EALDH1A1 | |
| SCHEMBL2684164 | 0.72 | KDM4E (0.39) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9840512-B2 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20160002255-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2016-01-07 | — | — | US | disclosed |
| US-20140045873-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045873-A1 | NOVEL MICROBIOCIDES | MSR1, CD209, C3AR1 | KDM4E 4167/4885ALDH1A1 884/4885 |
| US-20160002255-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | GPR119, GPR65, GLP1R | KDM4E 3801/4885ALDH1A1 2872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.